Affordable Access

deepdyve-link deepdyve-link
Publisher Website

EMAS position statement: Managing the menopause in women with a past history of endometriosis.

Authors
Type
Published Article
Journal
Maturitas
0378-5122
Publisher
Elsevier
Publication Date
Volume
67
Issue
1
Pages
94–97
Identifiers
DOI: 10.1016/j.maturitas.2010.04.018
PMID: 20627430
Source
Medline
License
Unknown

Abstract

The data regarding hormone therapy regimens are limited. However it may be safer to give either continuous combined estrogen-progestogen therapies or tibolone in both hysterectomised and nonhysterectomised women as the risk of recurrence may be reduced. The risk of recurrence with hormone therapy is probably increased in women with residual disease after surgery. Management of potential recurrence is best monitored by responding to recurrence of symptoms. Women not wanting estrogen or those who are advised against should be offered alternative pharmacological treatment for climacteric symptoms or skeletal protection if indicated. Herbal preparations should be avoided as their efficacy is uncertain and some may contain estrogenic compounds.

Statistics

Seen <100 times